Skip to content
value.today
Kyntra Bio, Inc. logo

Kyntra Bio, Inc.

KYNB
$79 Mlast known market cap, Jan 2024 — no current value
Compare
World rank
—
no current market cap
Revenue
$6 M
For year ending December-2025
Net income
$183 M
2848.6% margin
SEC filing
Employees
566
As on 2021
value.today research

Kyntra Bio, Inc. in brief

Kyntra Bio, Inc. is a listed company in the Biotechnology industry, based in California, USA. Its last known market value was $79 M (January 2024); there is no current figure. In the year to December 2025 it had sales of $6 M and a net profit of $183 M. It employs about 566 people and Thane Wettig is its chief executive. Its largest product and service lines by sales in 2025 were Drug Product Revenue, Net (91%) and Development and Other Revenue (9%). By market, the largest shares of its 2025 sales came from Europe (88%) and Japan (12%). Its shares trade under the symbol KYNB (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Kyntra Bio, Inc.

FibroGen is a Biotechnology company. It collaborating on the development and commercialization of roxadustat for the treatment of anemia in territories including Japan, Europe, the Commonwealth of Independent States, the Middle East and South Africa. The headquarters is in USA.

Kyntra Bio, Inc. timeline

4 events, 2002–2026
  1. 2002
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2014
  4. 🔔
    · approximate
    Initial public offering on Nasdaq
  5. 2019
  6. 💰
    Record revenue of $257 million
    FY2019, the highest of the 8 years on record.
  7. 2026
  8. ✎
    Renamed Kyntra Bio, Inc.
    Formerly Fibrogen Inc.

Events of Kyntra Bio, Inc. from SEC EDGAR, the company record and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$1.0 B$2.0 B$3.0 B$4.0 B20202021202220232024

World rank over time

▼ down 19,283 places since 2020
2020-01-01: #3351#3,35120202021-01-01: #3971#3,97120212022-01-07: #8306#8,30620222022-12-25: #6648#6,64820222023-07-30: #18400#18,40020232024-01-05: #22634#22,6342024

Rank in USA: #1,077 (Jan 2020) · #1,278 (Jan 2021) · #2,361 (Jan 2022) · #1,708 (Dec 2022) · #3,664 (Jul 2023) · #3,851 (Jan 2024)

Key ratios

market cap and latest results
P/E ratio
—
Price / sales
—
Price / book
—
Free cash flow yield
—
Net margin
2848.6%
Operating margin
-712.7%
Return on equity
—
Liabilities / assets
96.3%
Revenue growth
-78.3%
R&D / revenue
365.2%
Revenue per employee
$11 K
Profit per employee
$324 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $213M, net income $-86M$213MFY18Fiscal year ending Dec 2019: revenue $257M, net income $-77M$257MFY19Fiscal year ending Dec 2020: revenue $176M, net income $-189M$176MFY20Fiscal year ending Dec 2021: revenue $235M, net income $-290M$235MFY21Fiscal year ending Dec 2022: revenue $141M, net income $-294M$141MFY22Fiscal year ending Dec 2023: revenue $47M, net income $-284M$47MFY23Fiscal year ending Dec 2024: revenue $30M, net income $-48M$30MFY24Fiscal year ending Dec 2025: revenue $6M, net income $183M$6MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$6M-78.3%$-46M$183M2848.6%
Dec 2024$30M-36.7%$-150M$-48M-160.6%
Dec 2023$47M-66.7%$-323M$-284M-607.3%
Dec 2022$141M-40.2%$-301M$-294M-208.7%
Dec 2021$235M+33.5%$-289M$-290M-123.3%
Dec 2020$176M-31.3%$-192M$-189M-107.4%
Dec 2019$257M+20.5%$-89M$-77M-30.0%
Dec 2018$213M—$-87M$-86M-40.6%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-5M$0M$-5M$45.37—
Dec 2024$-138M$0M$-138M$-11.89—
Dec 2023$-315M$3M$-318M$-2.92—
Dec 2022$-146M$4M$-150M$-3.14—
Dec 2021$-82M$5M$-87M$-3.14—
Dec 2020$82M$4M$78M$-2.11—
Dec 2019$-79M$6M$-84M$-0.89—
Dec 2018$-76M$8M$-84M$-1.03—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Sep 2024: revenue $0M, net income $-17M$0MSep ’24Three months to Dec 2024 (from the annual report): revenue $3M, net income $18M$3MDec ’24Three months to Mar 2025: revenue $3M, net income $5M$3MMar ’25Three months to Jun 2025: revenue $1M, net income $-8M$1MJun ’25Three months to Sep 2025: revenue $1M, net income $201M$1MSep ’25Three months to Dec 2025 (from the annual report): revenue $1M, net income $-14M$1MDec ’25Three months to Mar 2026: revenue $4M, net income $-15M$4MMar ’26Three months to Jun 2026: revenue —, net income $12M—Jun ’26

Latest quarter to Jun 2026: revenue —, net income $12M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Kyntra Bio, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$6 M
Operating income
$-46 M
Net income
$183 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$120 M
Total liabilities
$115 M
Total equity
$-30 M

As of December-2025

Top 35 institutional investors in Kyntra Bio, Inc.#

As of Sep 30, 2026
35 institutions held 1.1 M shares (about 26.3% of the shares outstanding) on Sep 30, 2026. The ten largest hold 23.4%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Kyntra Bio, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Armistice Capital, LLC400,0000 (0.00%)9.88%$3 MNov 16, 2026
2Vanguard Capital Management LLC159,9500 (0.00%)3.95%$1 MNov 13, 2026
3Acadian Asset Management LLC105,5850 (0.00%)2.61%$1 MNov 9, 2026
4BlackRock, Inc.84,3300 (0.00%)2.08%$1 MNov 13, 2026
5Geode Capital Management, LLC41,387-1,832 (-4.24%)1.02%$0 MNov 6, 2026
6HighTower Advisors, LLC39,7460 (0.00%)0.98%$0 MNov 10, 2026
7Renaissance Technologies LLC35,281+8,200 (+30.28%)0.87%$0 MNov 12, 2026
8Two Sigma Investments, LP31,317-8,194 (-20.74%)0.77%$0 MNov 16, 2026
9Citadel Advisors LLC24,144New0.60%$0 MNov 16, 2026
10Vanguard Fiduciary Trust Co24,1050 (0.00%)0.60%$0 MNov 13, 2026
11Oppenheimer & Co Inc23,672New0.58%$0 MOct 26, 2026
12Birchview Capital, LP22,5660 (0.00%)0.56%$0 MNov 13, 2026
13State Street Corp20,2840 (0.00%)0.50%$0 MNov 12, 2026
14Gsa Capital Partners LLP20,161+4,464 (+28.44%)0.50%$0 MNov 16, 2026
15ADAR1 Capital Management, LLC14,341New0.35%$0 MNov 16, 2026
16UBS Group AG8,768+911 (+11.59%)0.22%$0 MNov 10, 2026
17Royal Bank Of Canada2,132+1,994 (+1444.93%)0.05%$0 MNov 16, 2026
18Vanguard Global Advisers, LLC1,4240 (0.00%)0.04%$0 MNov 13, 2026
19Group One Trading LLC1,116-3,290 (-74.67%)0.03%$0 MNov 10, 2026
20Axiom Investment Management LLC7040 (0.00%)0.02%$0 MNov 3, 2026
21Tower Research Capital LLC (TRC)567-546 (-49.06%)0.01%$0 MNov 16, 2026
22Morgan Stanley4870 (0.00%)0.01%$0 MNov 13, 2026
23Harbour Investments, Inc.2000 (0.00%)0.00%$0 MNov 9, 2026
24National Bank Of Canada /fi/1930 (0.00%)0.00%$0 MNov 16, 2026
25Nova Financial LLC1600 (0.00%)0.00%$0 MNov 4, 2026
Show all 35: investors 26 to 35
Institutional investors 26 to 35 in Kyntra Bio, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Osaic Holdings, Inc.102-80 (-43.96%)0.00%$0 MNov 12, 2026
27BNP Paribas Financial Markets460 (0.00%)0.00%$0 MNov 12, 2026
28SBI Securities Co., Ltd.16-136 (-89.47%)0.00%$0 MOct 22, 2026
29Jpmorgan Chase & Co120 (0.00%)0.00%$0 MNov 12, 2026
30FMR LLC8New0.00%$0 MNov 10, 2026
31Cassaday & Co Wealth Management LLC4New0.00%$0 MOct 27, 2026
32Barclays PLC3New0.00%$0 MNov 6, 2026
33CFG Wealth Management Services, Inc.3New0.00%$0 MOct 21, 2026
34Danske Bank A/s10 (0.00%)0.00%$0 MNov 9, 2026
35Smithfield Trust Co10 (0.00%)0.00%$0 MNov 9, 2026

Mutual funds holding Kyntra Bio, Inc.#

10 funds hold shares worth $1 M (about 4.9% of the company). Since their previous reports 2 added shares and 2 sold, buying $0 M net.
Mutual funds holding Kyntra Bio, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.114,179$1 M2.8%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.42,265$0 M1.0%<0.01%−0.4%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC21,079$0 M0.52%<0.01%−0.6%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC7,005$0 M0.17%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC5,744$0 M0.14%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.3,506$0 M0.09%<0.01%newJun 30, 2026
🇺🇸 Vanguard Capital Opportunity FundPRIMECAP Management Company2,716$0 M0.07%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC1,991$0 M0.05%<0.01%no changeMay 31, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC185$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC22$0 M<0.01%<0.01%+4.8%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 10 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Kyntra Bio, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$20 K
1 purchase, 1 insider
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$20 K
open market only
Insiders on file
30
since
$155 K$0Mar 2024: bought $96 K (1 trades), sold $0 (0 trades)Mar 24Jun 2024: bought $26 K (1 trades), sold $0 (0 trades)JunMar 2025: bought $155 K (3 trades), sold $0 (0 trades)MarJun 2025: bought $119 K (1 trades), sold $0 (0 trades)JunNov 2025: bought $34 K (2 trades), sold $0 (0 trades)NovMay 2026: bought $20 K (1 trades), sold $0 (0 trades)May
Bought (open market)Sold (open market)Hover a month for the totals
Kyntra Bio, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Thane WettigCEO, DirectorGrant or award+2,500$2.924$7 K29,296Form 4
filed David DeLuciaChief Financial OfficerShares withheld for tax-22$8.550$1884,355Form 4
filed Thane WettigCEO, DirectorShares withheld for tax-209$8.550$2 K26,796Form 4
filed Thane WettigCEO, DirectorShares withheld for tax-198$6.710$1 K27,005Form 4
filed David DeLuciaChief Financial OfficerShares withheld for tax-52$6.710$3494,377Form 4
filed Thane WettigCEO, DirectorBuyamended+2,800$7.090$20 K27,203Form 4/A
filed Thane WettigCEO, DirectorBuy-2,800$7.090$20 K27,203Form 4
filed David DeLuciaChief Financial OfficerShares withheld for tax-60$6.840$4104,429Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Kyntra Bio, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
95,811
2.4% of shares · 4.68 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2026-09-10 17:23 UTC, code LUDP, resumed 17:28 UTC
  • 2025-06-16 23:50 UTC, code T3, resumed 13:00 UTC

Fails to deliver

  • : 228 shares at $8.55
  • : 164 shares at $8.00
  • : 458 shares at $8.10
  • : 151 shares at $7.98
  • : 800 shares at $7.52

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Kyntra Bio, Inc. scorecard#

Passes 5 of the 14 checks that could be worked out: strongest in growth (2 of 6), weakest in profitability (1 of 4). Fiscal year 2025.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth2 of 6
    • ✗Revenue grew in the newest year-78.3%Revenue down 78.3% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-64.2%-64.2% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-64.2%-64.2% a year against Biotechnology's median of 12.9% (181 companies).
    • ✓Earnings per share grew in the newest year45.37 vs -11.89Diluted EPS 45.37 in fiscal 2025 against -11.89 the year before (report's currency).
    • ✓Net income higher than five years earlier$183 M$183 M in fiscal 2025 against -$189 M in 2020.
    • ✗Revenue rose in at least four of the last five years1 of 5Revenue rose in 1 of the five years to fiscal 2025.
  • Profitability1 of 4
    • ✓Profitable in the newest year$183 MNet income $183 M in fiscal 2025.
    • ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-712.7%-712.7% against Biotechnology's median of -60.5% (243 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✗Operating margin wider than three years earlier-712.7%-712.7% in fiscal 2025 against -213.9% in 2022.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities3.4×Current ratio 3.39 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times-5.2×Operating income -5.2 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns1 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✓Share count up no more than 2% in a year1.0%Diluted shares up 1.0% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Kyntra Bio, Inc.'s statements, beside the median of Biotechnology.

Kyntra Bio, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-712.7%-60.5%
Revenue growth, 3 years a year-64.2%12.9%
Revenue growth-78.3%15.8%
Free cash flow margin-74.7%-61.5%

4of 8on the Piotroski tests of financial strength

  • Revenue fell 78.3% against the year before.
  • Free cash flow was negative: -$5 million.
  • Only -3% of net income arrived as cash from operations.
  • Shareholders' equity is negative: -$30 million.

Kyntra Bio, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Kyntra Bio, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue6.43047r141235176257213131r183r
Cost of revenue0.6164.0r20138.91.1———
Research and development2496266r297387253209236197187
Selling, general and administrative284986r1251241061356452—
General and administrative———————645246
Operating expenses—————368346300248233
Total costs and expenses52180370r442524368346———
Operating income−46−150−323r−301−289−192−89−87−117r−50r
Interest expense and finance costs8.88.28.1r1.41.12.42.9119.711
Share of profit of associates——2.61.61.0−0.20———
Other non-operating income (expense)2.95.37.6r7.6−1.15.616———
Income before tax−58−153−323r−295−291−189r−77−86−121r−58r
Income tax−0.1−0.3−0.3r0.40.30.40.30.30.3−0.1
Income from discontinued operations24210639———————
Net income including minority interests183−48−284−294−290−189−77−86−121−58
Net income attributable to shareholders183−48−284−294−290−189−77−86−121r−58r
Earnings per share, basic45.37-11.89r-2.92-3.14-3.14-2.11-0.89-1.03-1.66r-0.93r
Earnings per share, diluted45.37-11.89r-2.92-3.14-3.14-2.11-0.89-1.03-1.66r-0.93r
Shares, weighted average (basic)4.04.0r97949290————
Shares, weighted average (diluted)4.04.0r9794929087847363
Balance sheet
Cash and cash equivalents485082r15617167812689674174
Short-term investments4101222662348.14075326279
Receivables0.20.55.1r16174228648.510
Inventory3.73.217r4031176.90——
Other current assets1.11.16.7r4.4r5.1r1.81.72.2r4.82.9
Current assets99197332493474755702690749267
Property, plant and equipment—04.8r21283443127129124
Right-of-use (leased) assets—065r80912.01.90——
Investments in associates——5.35.13.82.7————
Long-term investments200———0.2615611—
Total assets120215424610774827857881899470
Accounts payable3.75.116r3126256.19.15.56.2
Current liabilities291332182742251631038986r65
Lease liabilities (non-current)—065r80890.90.90——
Total liabilities115398586612545385322352351r294
Retained earnings−1,706−1,889−1,842−1,558−1,264−974−785−716−631r−510r
Shareholders' equity−30−226−204−21209422516509528r156
Minority interests———20201919191919
Total equity−17−205−184−1.5229441535528548r135r
Total liabilities and equity120215424610774827857881899470
Shares outstanding4.04.0r9994939188858264
Cash-flow statement
Share-based compensation6.6255166717366523832
Cash from operating activities−4.8−138−315−146−8282−79−76−677.1
Capital expenditure−0.0−0.3−2.5−3.7−5.2−4.0−5.8−8.0−8.5−1.3
Cash from investing activities3512615489−427452120−522706.6
Shares issued00.13.74.213382130359.9
Cash from financing activities−86−0.312347−0.613−4.3144966.7
Change in cash−54−12−42−16−50755237−58450020
Report10-K10-K10-K10-K10-K10-K10-K/A10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Kyntra Bio, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Drug Product Revenue, Net$6 M91%
  • Development and Other Revenue$1 M9.2%

Countries and regions

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Where Kyntra Bio, Inc. operates: 4 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 3 subsidiaries on file.

Kyntra Bio, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office—
🇰🇾 Cayman Islands2 subsidiaries—
🇫🇮 Finland1 subsidiary—
🇯🇵 Japan$1 M12%

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at Kyntra Bio, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$2.1 M
Thane Wettig
Other top executives, average
$1.1 M
the CEO earned 1.8× this
$100 invested is now
$2
Kyntra Bio, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Thane Wettig$2.1 M$1.5 M$1.1 M$2
2024Thane Wettig$2.6 M$1.5 M$1.0 M$3
2023Enrique Conterno, Thane Wettig$7.4 M−$4.8 M$3.1 M$6

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Kyntra Bio, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 3 · Acquisition or sale completed 1 · Directors and officers 4 · Material agreement 7 · Agreement ended 1 · New debt 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 3 · Shareholder vote 2 · Results announced 9

Kyntra Bio, Inc.: events reported to the SEC
FiledWhat happenedFiling
Delisting notice8-K
Directors and officers8-K
Material agreementNew debt8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Delisting notice8-K
Results announced8-K
Bylaws or fiscal year changed8-K
Results announced8-K
Acquisition or sale completed8-K
Material agreement8-K
Results announced8-K
Material agreement8-K
Agreement ended8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Directors and officersMaterial agreementShareholder vote8-K
Results announced8-K
Bylaws or fiscal year changed8-K
Material agreement8-K
Delisting noticeResults announced8-K
Material agreement8-K
Directors and officersMaterial agreementResults announced8-K
Directors and officers8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Oct 6, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Kyntra Bio, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2014$20 MNo. 1$10 to $50 million1equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Kyntra Bio, Inc.#

3 labor condition applications certified in fiscal 2025 for 3 positions, at a median wage of $120 K a year.

Certified, FY2025
3
#1,402 among companies on value.today
Worker positions
3
Median wage offered
$120 K
a year, full-time
Applications filed
3
Kyntra Bio, Inc.: most frequent H-1B job titles in fiscal 2025
Job titlePositionsMedian wage offered
Associate Scientist, Cell Line DevelopmentBiochemists and Biophysicists1$111 K
SAP Technical AnalystDatabase Architects1$120 K
Sr. Manager, ITComputer Systems Analysts1$168 K

Where: Atlanta, GA 1 · San Francisco, CA 1 · Plano, TX 1

Kyntra Bio, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202533$120 K3
FY20241010$134 K10
FY202388$144 K9
FY202255$131 K5
FY20211212$141 K12
FY202077$160 K7

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as FibroGen, Inc.

Layoffs at Kyntra Bio, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
231
2023–2024
Latest
—
2024-08-02
Kyntra Bio, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2024·······127····127
2023······104·····104
Kyntra Bio, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
Not statedRestructuring planSEC 8-KCompany-wide planFiling
effective 127 peopleLayoffWARN noticeSan Francisco, CaliforniaNotice list
effective 104 peopleLayoffWARN noticeSan Francisco, CaliforniaNotice list
104 peopleRestructuring planSEC 8-K“The Plan includes an expected reduction to the Company’s U.S. workforce of approximately 32% (or 104 employees).”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Kyntra Bio, Inc. compares in Biotechnology

  • Revenue$6 M · higher than 37% of 647
  • Revenue growth-78.3% · higher than 7% of 438

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Kyntra Bio, Inc.🇺🇸$79 M——-78.3%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jan 5, 2024 (last known)
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As on 2021
Profile updated:
Nov 16, 2026

Figures from SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Kyntra Bio, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Kyntra Bio, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Kyntra Bio, Inc.? Suggest a correction